Back to News
Market Impact: 0.15
Editas Medicine Names Dan Ory Chief Medical Officer
Source: Nasdaq
Healthcare & BiotechManagement & Governance
Editas Medicine appointed biotechnology executive Dan Ory as chief medical officer, effective September 8. The leadership change is a routine operational development with limited expected near-term market impact absent additional clinical, strategic, or financial details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
EDIT0.30
More News
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- With earnings in rearview mirror, SpaceX-Tesla merger chatter takes center stage
- J&J prostate cancer drug shows promising tumor responses in early trial
- ‘There’s nothing temporary about a temporary store’: How Spirit Halloween’s CEO took it from 130 stores to 1,550—and swallowed your mall’s Hot Topic
- ‘It wasn’t me, and I don’t think it was Elon’: Trump and his cabinet send mixed messages about what led to Ukraine’s Starshield interruptions